Event summary produced by The Globe and Mail Events team. The Globe’s editorial department was not involved.

Tesla stock rises sharply extending gains for a second day, Nvidia and Palantir shares trade higher as tech stocks bounce ...

Wondering if you should look beyond American markets to build your fortune? This widely held international fund offers a few ...

PARIS] Ozempic-maker Novo Nordisk is planning to make more of its medicines for the US market in the country; Boeing risks a ...

The report highlighted that Novo Nordisk currently charges Americans $969 a month for diabetes therapy Ozempic, but just $155 in Canada and $59 in Germany. Similarly, the list price for obesity ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

COPENHAGEN (Reuters) - Novo Nordisk (NYSE:NVO) has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NYSE:NVO) said on Friday ...

LONDON (Reuters) -Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff wars, hoping to avert price spikes on top-selling medicines ...

(Bloomberg) -- A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock. Kepler Cheuvreux’s David Evans ...

LONDON - The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-processed foods, after more than 90 ...